Substudy of Pilot study to assess virologic suppression and immune recovery associated with a simplified two-drug potent antiretroviral regimen of Raltegravir and Lopinavir/ritonavir (LPV/RTV) versus Raltegravir plus Emtricitabine/Tenofovir in treatment-n